fluorouracil has been researched along with Aberrant Crypt Foci in 5 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Aberrant Crypt Foci: Clusters of colonic crypts that appear different from the surrounding mucosa when visualized after staining. They are of interest as putative precursors to colorectal adenomas and potential biomarkers for colorectal carcinoma.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study, we examined the potential of DECPR to prevent colon cancer development in rats treated with azoxymethane (AOM) (15 mg/kg) by determining the percentage inhibition in incidence of aberrant crypt foci (ACF)." | 7.81 | The chemopreventive potential of Curcuma purpurascens rhizome in reducing azoxymethane-induced aberrant crypt foci in rats. ( Abd Malek, SN; Abdulla, MA; Al-Henhena, N; Awang, K; Hasanpourghadi, M; Kunasegaran, T; Looi, CY; Moghadamtousi, SZ; Mohamed, Z; Rouhollahi, E, 2015) |
| "The present study investigated whether a water-soluble extract from the culture medium of Ganoderma lucidum mycelia (Japanese: Reishi or Mannentake) (designated as MAK) exerted a protective effect against induction of aberrant crypt foci (ACF) by azoxymethane (AOM) and small-intestinal damage induced by the anticancer drug 5-FU." | 7.79 | Effects of a water-soluble extract of Ganoderma lucidum mycelia on aberrant crypt foci induced by azoxymethane and small-intestinal injury by 5-FU in F344 rats. ( Kashimoto, N; Tamura, K; Ushijima, M; Watanabe, H, 2013) |
| " In vivo pellet coating led to reduced drug bioavailability and enhanced drug accumulation at colon (179." | 5.40 | Oral 5-fluorouracil colon-specific delivery through in vivo pellet coating for colon cancer and aberrant crypt foci treatment. ( Bose, A; Elyagoby, A; Wong, TW, 2014) |
| " In the present study, we examined the potential of DECPR to prevent colon cancer development in rats treated with azoxymethane (AOM) (15 mg/kg) by determining the percentage inhibition in incidence of aberrant crypt foci (ACF)." | 3.81 | The chemopreventive potential of Curcuma purpurascens rhizome in reducing azoxymethane-induced aberrant crypt foci in rats. ( Abd Malek, SN; Abdulla, MA; Al-Henhena, N; Awang, K; Hasanpourghadi, M; Kunasegaran, T; Looi, CY; Moghadamtousi, SZ; Mohamed, Z; Rouhollahi, E, 2015) |
| "The present study investigated whether a water-soluble extract from the culture medium of Ganoderma lucidum mycelia (Japanese: Reishi or Mannentake) (designated as MAK) exerted a protective effect against induction of aberrant crypt foci (ACF) by azoxymethane (AOM) and small-intestinal damage induced by the anticancer drug 5-FU." | 3.79 | Effects of a water-soluble extract of Ganoderma lucidum mycelia on aberrant crypt foci induced by azoxymethane and small-intestinal injury by 5-FU in F344 rats. ( Kashimoto, N; Tamura, K; Ushijima, M; Watanabe, H, 2013) |
| " In vivo pellet coating led to reduced drug bioavailability and enhanced drug accumulation at colon (179." | 1.40 | Oral 5-fluorouracil colon-specific delivery through in vivo pellet coating for colon cancer and aberrant crypt foci treatment. ( Bose, A; Elyagoby, A; Wong, TW, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Socca, EAR | 1 |
| Reis, SK | 1 |
| Genaro, SC | 1 |
| Leite, SK | 1 |
| Reis, IB | 1 |
| Bockëlmann, PK | 1 |
| Durán, N | 1 |
| Fávaro, WJ | 1 |
| Bose, A | 1 |
| Elyagoby, A | 1 |
| Wong, TW | 1 |
| Wang, K | 1 |
| Kim, MK | 1 |
| Di Caro, G | 1 |
| Wong, J | 1 |
| Shalapour, S | 1 |
| Wan, J | 1 |
| Zhang, W | 1 |
| Zhong, Z | 1 |
| Sanchez-Lopez, E | 1 |
| Wu, LW | 1 |
| Taniguchi, K | 1 |
| Feng, Y | 1 |
| Fearon, E | 1 |
| Grivennikov, SI | 1 |
| Karin, M | 1 |
| Rouhollahi, E | 1 |
| Moghadamtousi, SZ | 1 |
| Al-Henhena, N | 1 |
| Kunasegaran, T | 1 |
| Hasanpourghadi, M | 1 |
| Looi, CY | 1 |
| Abd Malek, SN | 1 |
| Awang, K | 1 |
| Abdulla, MA | 1 |
| Mohamed, Z | 1 |
| Watanabe, H | 1 |
| Kashimoto, N | 1 |
| Ushijima, M | 1 |
| Tamura, K | 1 |
5 other studies available for fluorouracil and Aberrant Crypt Foci
| Article | Year |
|---|---|
P-mapa, a promisor immunomodulator against tumor cells of colonic tissues: An investigation of the action mechanism over the TLR4 signaling pathway.
Topics: Aberrant Crypt Foci; Animals; Antineoplastic Agents; Biopolymers; Colonic Neoplasms; Enzyme-Linked I | 2020 |
Oral 5-fluorouracil colon-specific delivery through in vivo pellet coating for colon cancer and aberrant crypt foci treatment.
Topics: Aberrant Crypt Foci; Adenocarcinoma; Adenoma; Administration, Oral; Animals; Antimetabolites, Antine | 2014 |
Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis.
Topics: Aberrant Crypt Foci; Animals; Antibodies, Blocking; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
The chemopreventive potential of Curcuma purpurascens rhizome in reducing azoxymethane-induced aberrant crypt foci in rats.
Topics: Aberrant Crypt Foci; Animals; Antioxidants; Apoptosis; Azoxymethane; Chemoprevention; Colonic Neopla | 2015 |
Effects of a water-soluble extract of Ganoderma lucidum mycelia on aberrant crypt foci induced by azoxymethane and small-intestinal injury by 5-FU in F344 rats.
Topics: Aberrant Crypt Foci; Animals; Azoxymethane; Colonic Neoplasms; Culture Media; Fluorouracil; Intestin | 2013 |